Inhibitory Effect of PPARδ Agonist GW501516 on Proliferation of Hypoxia-induced Pulmonary Arterial Smooth Muscle Cells by Regulating the mTOR Pathway

Abstract

Objective

This study aimed to investigate the effects of the peroxisome proliferator-activated receptor δ (PPARδ) agonist GW501516 on the proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia, in order to search for new drugs for the treatment and prevention of pulmonary vascular remodeling.

Methods

PASMCs were incubated with different concentrations of GW501516 (10, 30, 100 nmol/L) under the hypoxic condition. The proliferation was determined by a CCK-8 assay. The cell cycle progression was analyzed by flow cytometry. The expression of PPARδ, S phase kinase-associated protein 2 (Skp2), and cell cycle-dependent kinase inhibitor p27 was detected by Western blotting. Then PASMCs were treated with 100 nmol/ L GW501516, 100 nmol/L mammalian target of rapamycin (mTOR) inhibitor rapamycin and/or 2 µmol/L mTOR activator MHY1485 to explore the molecular mechanisms by which GW501516 reduces the proliferation of PASMCs.

Results

The presented data demonstrated that hypoxia reduced the expression of PPARδ in an oxygen concentration- and time-dependent manner, and GW501516 decreased the proliferation of PASMCs induced by hypoxia by blocking the progression through the G0/G1 to S phase of the cell cycle. In accordance with these findings, GW501516 downregulated Skp2 and upregulated p27 in hypoxia-exposed PASMCs. Further experiments showed that rapamycin had similar effects as GW501516 in inhibiting cell proliferation, arresting the cell cycle, regulating the expression of Skp2 and p27, and inactivating mTOR in hypoxia-exposed PASMCs. Moreover, MHY1485 reversed all the beneficial effects of GW501516 on hypoxia-stimulated PASMCs.

Conclusion

GW501516 inhibited the proliferation of PASMCs induced by hypoxia through blocking the mTOR/Skp2/p27 signaling pathway.

Keywords

peroxisome proliferator-activated receptor δ / GW501516 / hypoxia / pulmonary artery smooth muscle cells / proliferation / mammalian target of rapamycin

References

[1] ChaiT, QiuC, XianZ, et al.. A narrative review of research advances in hypoxic pulmonary hypertension. Ann Transl Med, 2022, 10(4): 230

[2] LiC, ZhuH, ZhangS, et al.. Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response. Phytomedicine, 2022, 102: 154171

[3] RajagopalS, YuYA. The Pathobiology of Pulmonary Arterial Hypertension. Cardiol Clin, 2022, 40(1): 1-12

[4] HuHH, ZhangRF, DongLL, et al.. Overexpression of ACE2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PASMCs. Eur Rev Med Pharmacol Sci, 2020, 24(7): 3968-3980

[5] LiuY, NieX, ZhuJ, et al.. NDUFA4L2 in smooth muscle promotes vascular remodeling in hypoxic pulmonary arterial hypertension. J Cell Mol Med, 2021, 25(2): 1221-1237

[6] WangAP, YangF, TianY, et al.. Pulmonary Artery Smooth Muscle Cell Senescence Promotes the Proliferation of PASMCs by Paracrine IL-6 in Hypoxia-Induced Pulmonary Hypertension. Front Physiol, 2021, 12: 656139

[7] LiuX, WangG, YouZ, et al.. Inhibition of hypoxia induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector. Biomaterials, 2014, 35: 4401-4416

[8] ZhaLH, ZhouJ, TanY, et al.. NLRC3 inhibits PDGF-induced PASMCs proliferation via PI3K-mTOR pathway. J Cell Physiol, 2020, 235(12): 9557-9567

[9] KrymskayaVP, SnowJ, CesaroneG, et al.. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J, 2011, 25(6): 1922-1933

[10] SongY, WuY, SuX, et al.. Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms. Pharmacol Res, 2016, 107: 117-124

[11] KeR, LiuL, ZhuY, et al.. Knockdown of AMPKα2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway. Int J Mol Sci, 2016, 17(6): 844

[12] DegueurceG, D’ErricoI, PichC, et al.. Identification of a novel PPARbeta/delta/miR-21-3p axis in UV-induced skin inflammation. EMBO Mol Med, 2016, 8(8): 919-936

[13] CheangWS, WongWT, ZhaoL, et al.. PPARδ Is Required for Exercise to Attenuate Endoplasmic Reticulum Stress and Endothelial Dysfunction in Diabetic Mice. Diabetes, 2017, 66(2): 519-528

[14] KintzP, AmelineA, GheddarL, et al.. Testing for G W501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal, 2020, 12(7): 980-986

[15] WeihrauchM, HandschinC. Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls. Biochem Pharmacol, 2018, 147: 211-220

[16] HwangJS, HamSA, YooT, et al.. Sirtuin 1 Mediates the Actions of Peroxisome Proliferator-Activated Receptor δ on the Oxidized Low-Density Lipoprotein–Triggered Migration and Proliferation of Vascular Smooth Muscle Cells. Mol Pharmacol, 2016, 90(5): 522-529

[17] KangES, HwangJS, LeeWJ, et al.. Ligand-activated PPARdelta inhibits angiotensin II-stimulated hypertrophy of vascular smooth muscle cells by targeting ROS. PLoS One, 2019, 14(1): e0210482

[18] ZhangS, WangJ, QiX, et al.. Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling. Exp Cell Res, 2021, 398(1): 112392

[19] ChenC, TangY, DengW, et al.. Salidroside blocks the proliferation of pulmonary artery smooth muscle cells induced by platelet derived growth factor BB. Mol Med Rep, 2014, 10(2): 917-922

[20] GuiD, CuiZ, ZhangL, et al.. Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway. BMC Pulm Med, 2017, 17(1): 191

[21] JeongK, MurphyJM, AhnEE, et al.. FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation. Cardiovasc Res, 2022, 118(4): 1150-1163

[22] LiuL, PanY, SongY, et al.. Activation of AMPK α2 inhibits airway smooth muscle cells proliferation. Eur J Pharmacol, 2016, 791: 235-243

[23] ParikhV, BhardwajA, NairA. Pharmacotherapy for pulmonary arterial hypertension. J Thorac Dis, 2019, 11(Suppl14): S1767-S1781

[24] DengH, TianX, SunH, et al.. Calpain-1 mediates vascular remodelling and fibrosis via HIF-lα in hypoxia-induced pulmonary hypertension. J Cell Mol Med, 2022, 26(10): 2819-2830

[25] NanX, YangZ, SuS, et al.. The Mechanism of Volatile Oil of Rhodiola tangutica against Hypoxia-Induced Pulmonary Hypertension in Rats Based on RAS Pathway. Biomed Res Int, 2022, 2022: 9650650

[26] TianD, TengX, JinS, et al.. Endogenous hydrogen sulfide improves vascular remodeling through PPARdelta/ SOCS3 signaling. J Adv Res, 2020, 27: 115-125

[27] HytönenJ, LeppänenO, BraesenJH, et al.. Activation of Peroxisome Proliferator-Activated Receptor-delta as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis. Arterioscler Thromb Vasc Biol, 2016, 36(8): 1534-1548

[28] FoutyBW, GrimisonB, FaganKA, et al.. p27(Kip1) is important in modulating pulmonary artery smooth musclecell proliferation. Am J Respir Cell Mol Biol, 2001, 25(5): 652-658

[29] ChenMJ, ChengAC, LeeMF, et al.. Simvastatin induces G(1) arrest by up-regulating GSK3β and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. J Cell Physiol, 2018, 233(6): 4618-4625

[30] LuanL, LiN, ZhangK, et al.. Diversin upregulates the proliferative ability of colorectal cancer by inducing cell cycle proteins. Exp Mol Pathol, 2023, 129: 104850

[31] FujitaT, LiuW, DoiharaH, et al.. Regulation of Skp2-p27 axis by the Cdh1/anaphase-promoting complex pathway. Am J Pathol, 2008, 173(1): 217-228

[32] ZhangH, GongY, WangZ, et al.. Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia. J Cell Mol Med, 2014, 18(3): 542-553